| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3226 |
| Trial ID | NCT05607420 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD20|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | UCAR-T20x22 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma |
| Year | 2022 |
| Country | Spain |
| Company sponsor | Cellectis S.A. |
| Other ID(s) | UCART20x22_01 |
| Cohort 1 | |||||||||||
|
|||||||||||